Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Compugen Ltd CGEN

Healthcare Biotechnology
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company... see more

Recent & Breaking News (NDAQ:CGEN)

Compugen Announces Addition of Prof. Miriam Merad to Its Scientific Advisory Board

PR Newswire March 8, 2017

Compugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery Methodology for Novel Immune Checkpoints at AACR

PR Newswire March 2, 2017

Compugen Reports Fourth Quarter and Calendar Year 2016 Results

PR Newswire February 15, 2017

Compugen Fourth Quarter and Yearend 2016 Conference Call Scheduled for Wednesday, February 15, 2017 at 10:00 AM EST

PR Newswire January 30, 2017

Compugen's CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity

PR Newswire January 4, 2017

Compugen Announces Key Highlights from R&D Day

PR Newswire December 7, 2016

Compugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint

PR Newswire December 7, 2016

Compugen Appoints Senior Vice President Corporate and Business Development

PR Newswire December 5, 2016

Compugen to Present at 28th Annual Piper Jaffray Healthcare Conference in New York

PR Newswire November 21, 2016

Compugen Immune Checkpoint Program Demonstrates Potential for Development of New Cancer Immunotherapy Treatments

PR Newswire November 11, 2016

Compugen Ltd. Reports 3rd Quarter 2016 Financial Results

PR Newswire November 7, 2016

Compugen to Host R&D Day on December 7, 2016 in New York

PR Newswire November 3, 2016

Compugen Third Quarter Financial Statements to be Released November 7, 2016

PR Newswire October 10, 2016

Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month

PR Newswire October 7, 2016

Compugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunotherapy

PR Newswire August 30, 2016

Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program

PR Newswire June 22, 2016

Compugen to Present at JMP Securities Life Sciences Conference in New York

PR Newswire June 15, 2016

Compugen to Present at the Jefferies Global Healthcare Conference in New York

PR Newswire May 23, 2016

Compugen to Present at the Oppenheimer Annual Israeli Conference in Tel Aviv

PR Newswire May 16, 2016

Compugen Ltd. Reports First Quarter 2016 Financial Results

PR Newswire May 10, 2016